Does Ketamine Therapy Get You High and How Medical Ketamine Treatment Actually Works

The short answer is: not exactly. Does ketamine therapy get you high is one of the most common questions patients ask before their first session, and it deserves an honest, nuanced answer. Medical ketamine does produce altered perceptual states at therapeutic doses, but those experiences differ fundamentally from recreational intoxication in purpose, intensity, context, and outcome.

Understanding the distinction helps patients approach treatment with accurate expectations rather than anxiety or unrealistic assumptions. Additionally, it helps families and caregivers support loved ones through a legitimate medical process without conflating it with substance misuse.

What Ketamine Actually Does in the Brain

Ketamine works primarily by blocking NMDA (N-methyl-D-aspartate) receptors in the brain, which triggers a rapid surge of glutamate, the brain's most abundant excitatory neurotransmitter. This surge stimulates AMPA receptors and promotes the release of BDNF (brain-derived neurotrophic factor), a protein that supports the growth and strengthening of neural connections.

As a result, ketamine rapidly increases neuroplasticity, the brain's ability to form new pathways and reorganize existing ones.

This mechanism is fundamentally different from how traditional antidepressants work. SSRIs and SNRIs modulate serotonin and norepinephrine levels over weeks. In contrast, ketamine's glutamate-driven action produces measurable antidepressant effects within hours to days, making it particularly valuable for treatment-resistant depression and acute suicidality.

Furthermore, the enhanced neuroplasticity window created after a ketamine session is believed to make the brain more receptive to therapy and behavioral change.

Does Ketamine Therapy Get You High: The Honest Answer

Therapeutic ketamine does produce dissociative effects at medical doses, but calling them a "high" in the recreational sense is inaccurate and misleading. Patients in clinical settings typically experience mild to moderate dissociation, which manifests as a feeling of detachment from the body, altered perception of time and space, dreamlike visual phenomena, and a sense of floating or lightness. These effects are transient, typically lasting 45 to 90 minutes during an infusion session, and resolve completely as the drug clears the system.

Recreational ketamine use seeks these dissociative effects as the primary goal, often at doses two to four times higher than therapeutic levels. In contrast, medical ketamine therapy uses the dissociative state as a controlled side effect of a precisely dosed neurological treatment.

The intent is healing, not intoxication. Therefore, the subjective experience, while sometimes unusual or vivid, occurs within a structured clinical environment with continuous medical monitoring rather than in an unsupervised social context.

Medical vs Recreational Ketamine: Key Differences

Dosage: Therapeutic doses are precisely calibrated based on body weight and clinical protocol; recreational doses are unregulated and often significantly higher, dramatically increasing risk.

Drug quality: Medical ketamine is pharmaceutical-grade and free of contaminants; street ketamine is frequently adulterated with unknown substances that multiply health risks.

Administration method: Clinical ketamine is delivered intravenously, intramuscularly, or via FDA-approved nasal spray (esketamine) with controlled absorption rates; recreational use typically involves snorting or oral ingestion with unpredictable pharmacokinetics.

Monitoring: Medical sessions involve continuous tracking of blood pressure, oxygen saturation, respiratory rate, and cardiac rhythm by qualified clinicians; recreational use provides none of this safety infrastructure.

Intention and context: Therapeutic ketamine is administered with a defined healing goal integrated into a broader treatment plan; recreational use has no clinical framework and no professional support before, during, or after the experience.

Frequency and duration: Treatment courses are time-limited (typically six infusions over two to three weeks for depression protocols); recreational use patterns often involve escalating frequency and dose to maintain desired effects.

What Patients Actually Experience During a Therapeutic Session

Most patients describe the experience as profoundly relaxing and introspective rather than euphoric or chaotic. Common sensations include a gentle separation from ordinary thinking patterns, visual phenomena like shifting colors or geometric forms, and an unusual emotional openness that many describe as helpful for processing difficult feelings.

Some patients report deeply meaningful insights or a reduction in the emotional charge surrounding painful memories, which supports the therapeutic process.

Side effects during sessions may include mild nausea, elevated blood pressure, lightheadedness, and temporary confusion during the transition back to full alertness. Clinics typically provide an anti-nausea medication beforehand and monitor vital signs continuously to manage these effects.

Additionally, patients receive clear preparation instructions including fasting guidelines and arrangements for supervised transport home, since driving is not permitted for the remainder of the day following a session.

Conditions Treated With Ketamine Therapy

Ketamine therapy has demonstrated clinically meaningful results across several challenging mental health and pain conditions, particularly in patients who have not responded to conventional treatments.

Treatment-resistant depression (TRD): The most established application; multiple randomized controlled trials confirm rapid symptom reduction in patients who failed two or more adequate antidepressant trials.

Major depressive disorder with suicidal ideation: Ketamine's rapid onset makes it uniquely valuable for acute situations where traditional antidepressants take too long to act.

Post-traumatic stress disorder (PTSD): Emerging evidence suggests the dissociative state allows patients to process traumatic memories with reduced emotional reactivity, supporting PTSD symptom reduction.

Generalized anxiety disorder and social anxiety: Clinical studies report significant symptom reduction in anxiety disorders, though research is less mature than for depression.

Bipolar depression: Shows promise for depressive episodes in bipolar disorder, though careful patient selection and monitoring are required due to the risk of triggering manic states.

Chronic neuropathic pain: Ketamine's NMDA receptor blockade disrupts central sensitization pathways that drive conditions like complex regional pain syndrome (CRPS) and fibromyalgia.

Addiction and Dependency Risk in Therapeutic Ketamine Use

One of the most important questions surrounding ketamine therapy is whether supervised medical use carries meaningful addiction risk. The consensus among addiction medicine specialists is that properly administered therapeutic ketamine poses a significantly lower addiction risk than recreational use, though it is not zero.

Recreational ketamine use at high doses and high frequencies can produce psychological dependence, tolerance, and compulsive use behaviors. In contrast, medical protocols limit session frequency, cap the total number of induction treatments, and include ongoing clinical assessment between sessions specifically to monitor for dependency signals.

Furthermore, the controlled clinical environment removes the behavioral reinforcement patterns that drive recreational substance dependence, since patients are not self-administering the drug or managing their own dosing decisions at any point.

Patients with a personal or family history of substance use disorders require additional screening and monitoring before ketamine therapy is approved. However, this history is not automatically disqualifying, and many addiction specialists consider the benefit-risk calculation favorable for carefully selected patients with severe treatment-resistant conditions.

FDA Approval and the Regulatory Landscape

Esketamine (Spravato), a nasal spray formulation of ketamine's S-enantiomer, received FDA approval in 2019 for treatment-resistant depression and, shortly after, for major depressive disorder with suicidal ideation. This approval requires administration in a certified healthcare setting with a minimum two-hour observation period after each dose, further distinguishing it from any self-administered or unsupervised use.

Racemic ketamine infusion therapy, while widely used clinically, remains an off-label application. This means physicians prescribe and administer it outside its original FDA-approved anesthesia indication, which is common and legal in medical practice but means standardized protocols vary between providers.

Therefore, patients seeking ketamine infusion therapy should verify that their provider follows evidence-based dosing guidelines and maintains full clinical monitoring infrastructure throughout each session.

What to Expect Before, During, and After Treatment

Preparation begins with a thorough psychiatric and medical evaluation to confirm candidacy and rule out contraindications including uncontrolled hypertension, active psychosis, and certain cardiovascular conditions. Patients typically fast for several hours before each session and arrange a responsible adult to accompany them home afterward.

During the session, patients recline in a comfortable clinical environment, often with an eye mask and calming music to support an inward, reflective experience. Medical staff remain present throughout to monitor vitals and provide reassurance if anxiety arises. After the infusion ends, the most pronounced dissociative effects resolve within 30 to 60 minutes, though mild cognitive effects may persist for a few hours.

Integration therapy between sessions significantly amplifies outcomes. Working with a therapist to process insights and emotional material that surface during ketamine sessions helps translate the neuroplasticity window into lasting behavioral and psychological change. Many providers now offer dedicated integration support as a standard component of the treatment program rather than an optional add-on.